<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03583567</url>
  </required_header>
  <id_info>
    <org_study_id>Si 2018</org_study_id>
    <nct_id>NCT03583567</nct_id>
  </id_info>
  <brief_title>Effect of Anti-histamine in Prevention Systolic Hypotension After Protamine</brief_title>
  <official_title>A Randomized Controlled Study Comparing the Prophylactic Effect of histamine1 and Histamine 2 Receptor Blocker in Prevention Systolic Hypotension After Protamine Administration in Cardiac Patient Having Cardiopulmonary Bypass</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Mahidol University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Mahidol University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Protamine remains the anticoagulant of choice for cardiopulmonary bypass (CPB). The process
      of protamine neutralization of heparin came with the side effects sometimes; it can be life
      threatening or fetal reaction. The adverse cardiopulmonary response of protamine has been
      observed during entire history of clinical cardiac surgery. The true mechanism reaction is
      difficult to defined and the complexity of the clinical situation The classification of
      protamine reaction has been divided in to main 3 types (transient systemic hypotension
      secondary to rapid administration, anaphylactic and anaphylactoid reaction and catastrophic
      pulmonary vasoconstriction.

      The reaction from pharmacologic histamine release is the most common type of reaction.
      Protamine was believed to induce hypotension by this mechanism, and it was demonstrated to
      release histamine by degranulation of isolated mast cells From the hypothesis that the
      systemic hypotension cause by the released of histamine. The investigators will measure the
      serum tryptase which is the enzyme that released from degranulation of human mast cell.
      Comparing the serum tryptase level of the patient at baseline, 30 min and 60 min after
      protamine was given.

      There for the hypothesis of this study is administrating of H1 and H2 blocker helps attenuate
      the drop in MAP after protamine is given.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 5, 2018</start_date>
  <completion_date type="Anticipated">December 1, 2020</completion_date>
  <primary_completion_date type="Anticipated">December 1, 2020</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
    <masking_description>normal saline will be used as placebo in control group</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Blood pressure</measure>
    <time_frame>37 minutes</time_frame>
    <description>Systolic and diastolic blood pressure will be recorded every minutes since the start of protamine infusion (in 7 minutes) til 30 minutes after infusion.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Serum tryptase</measure>
    <time_frame>60 minutes</time_frame>
    <description>Serum tryptase will be measured before the administration of protamine and at 30 minutes and 60 minutes after protamine</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Protamine Adverse Reaction</condition>
  <arm_group>
    <arm_group_label>0.9% Normal Saline</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Syringe No 1 contain normal saline 1 mL Syringe No 2 contain normal saline 2 mL</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Chlorpheniramine and ranitidine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Syringe No 1 contain chlorpheniramine 10 mg (1 mL) Syringe No 2 contain ranitidine 50 mg (2 mL)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Chlorpheniramine and ranitidine</intervention_name>
    <description>Patient will receive intravenous chlorpheniramine and ranitidine prior to protamine.</description>
    <arm_group_label>Chlorpheniramine and ranitidine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>0.9% Normal Saline</intervention_name>
    <description>Patient will receive normal saline as placebo.</description>
    <arm_group_label>0.9% Normal Saline</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  ASA physical status 1-3

          -  Schedule for open heart surgery

        Exclusion Criteria:

          -  History of allergy to the study drugs or protamine

          -  History of previous cardiac surgery or received protamine

          -  History of diabetes with insulin therapy
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sirilak Suksompong, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Mahidol University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>sirilak Suksompong, MD</last_name>
    <phone>66891534806</phone>
    <email>ssuksompong5@gmail.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Siriraj Hospital</name>
      <address>
        <city>Bangkok</city>
        <zip>10700</zip>
        <country>Thailand</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sirilak Suksompoong, MD</last_name>
      <email>ssuksompong5@gmail.com</email>
    </contact>
  </location>
  <location_countries>
    <country>Thailand</country>
  </location_countries>
  <verification_date>September 2018</verification_date>
  <study_first_submitted>June 7, 2018</study_first_submitted>
  <study_first_submitted_qc>June 28, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">July 11, 2018</study_first_posted>
  <last_update_submitted>September 24, 2018</last_update_submitted>
  <last_update_submitted_qc>September 24, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">September 25, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>protamine</keyword>
  <keyword>antihistamine</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypotension</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Chlorpheniramine</mesh_term>
    <mesh_term>Ranitidine</mesh_term>
    <mesh_term>Ranitidine bismuth citrate</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

